This study also indicated that crizotinib has promising efficacy in ALK‐positive Chinese lung adenocarcinoma patients who received it as a second‐line treatment after PD had occurred on first‐line chemotherapy, with a median PFS of about 10 months and an ORR of more than 60% in these patients. This evidence concerns the gene ALK and lung adenocarcinoma.